MEI Pharma (MEIP) Financials

MEI Pharma, Inc. (MEIP) reported diluted earnings per share of -$2.39 for fiscal year 2025. This represents a -189.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

MEI Pharma, Inc. (MEIP) had EBITDA of -$17.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

MEI Pharma, Inc. (MEIP) has a return on equity of -94.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

MEI Pharma, Inc. (MEIP) recorded an outflow of $20.8M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

MEI Pharma, Inc. (MEIP) recorded an outflow of $20.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

MEI Pharma, Inc. (MEIP) had $18.3M in total assets as of fiscal year 2025, including both current and long-term assets.

MEI Pharma, Inc. (MEIP) reported no capital expenditure during fiscal year 2025.

MEI Pharma, Inc. (MEIP) invested $3.9M in research and development during fiscal year 2025.

MEI Pharma, Inc. (MEIP) had 7M shares outstanding as of fiscal year 2025.

MEI Pharma, Inc. (MEIP) had a current ratio of 13.50 as of fiscal year 2025, which is generally considered healthy.

MEI Pharma, Inc. (MEIP) had a liabilities-to-equity ratio of 0.08 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

MEI Pharma, Inc. (MEIP) had a return on assets of -87.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

MEI Pharma, Inc. (MEIP) has an Altman Z-Score of 11.69, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

MEI Pharma, Inc. (MEIP) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

MEI Pharma, Inc. (MEIP) reported a net loss of $15.9M while operations used $20.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.